Mode
Text Size
Log in / Sign up
N/A N=101

Evaluation of the DPP HIV 1/2 Test and the HIV 1/2 Stat Pak Test Using Oral Fluid

HIV Infections

Enrolled (actual)
101
Serious AEs
0.0%
Results posted
Feb 2010
Primary outcome: Primary: Number of Fresh Oral Fluid Samples With Known HIV (+) Status and HIV Reactivity — 100 samples

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Pediatric, Adult, Older Adult · 12+ yrs
Sex
All
Sponsor
Chembio Diagnostic Systems, Inc.
Primary completion
Jul 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Fresh Oral Fluid Samples With Known HIV (+) Status and HIV Reactivity
100
SECONDARY
The Effectiveness of MPC and Chembio Oral Fluid Collection Devices

Summary

This protocol is intended to test the feasibility of using the HIV 1/2 STAT-PAK and the DPP HIV 1/2 test (with and without the DPP Handheld Reader) to detect HIV antibodies in oral fluids.

Eligibility Criteria

Inclusion Criteria

  • Participants with known HIV infection who are willing to participate in the study and who sign an informed consent (or assent), will be included in the study.
  • Patients on HAART treatment for HIV will be included, but this information as well as the dates (duration) of treatment will be obtained through the interview of study participants; a medical record review is not necessary or required. The study participant's responses will be recorded by study staff on a Data Collection Form.
  • Patients with immunosuppressive conditions other than HIV will be included if available, but will be limited to < 25% of the total test population. Immunosuppression will also be assessed through interview of study participants and/or through verbal confirmation by the treating physician; a medical record/chart review is not required.
  • Patients must be willing to undergo venipuncture to donate one tube of EDTA whole blood (not more than 10cc), and to provide three oral fluid samples.

Exclusion Criteria

  • Patients who do not consent, withdraw consent, or for whom the investigator determines that venipuncture or gum swabbing may create a health risk will be excluded from the study.
  • Participants who have been enrolled in HIV vaccine studies will be excluded from the study. This will be ascertained through interview of study participants.
  • Participants who have been enrolled once in this study will be excluded from repeat enrollment.
  • Participants must not have introduced any substance into their oral cavity (gum, food, beverage, candy, lozenges, mouthwash, etc.) for 30 minutes prior to providing an oral fluid sample. This will be ascertained through interview of study participants.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00636220). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search